A report has found that the dominant force in marketed gastric cancer drugs could be overtaken by more innovative treatments.
The report from business intelligence provider GBI Research states that while 99% of currently marketed gastric cancer drugs are small molecules, this dominance could give way in the future as the pipeline consists of 29% monoclonal antibodies (mAbs).
There are currently 241 products in the gastric cancer pipeline, a number of which have different mechanisms of action and targets to the dominant therapies on the market.
Associate Analyst Firas Nour said: “While Herceptin and Cyramza are the only mAbs currently on the market for gastric cancer, mAbs have shown strong clinical results and advantageous properties in numerous oncology indications, meaning they account for a relatively large proportion of many oncology pipelines.
“Data suggest that some biologics, such as mAbs, have more favourable risk profiles and, due to their higher target specificity, frequently perform more strongly in terms of both safety and efficacy than their synthetic counterparts.”
GBI Research also states that the innovative gastric cancer pipeline will allow the treatment space to become more diverse and less reliant on highly cytotoxic chemotherapy regimens, providing hope for sufferers now facing low survival rates.